Fig. 1.

Study design of the four arms in the phase 1/2a trial. Different pre-dosing (given approximately 1–3 h before ¹⁷⁷Lu-lilotomab satetraxetan injection) and pre-treatment regimens are shown in parallel. The anti-CD20 antibody rituximab was given to all patients, while only arms 1 and 4 patients received cold lilotomab (anti-CD37 antibody). The zero-hour timepoint of the grey timeline is set according to the administration of ¹⁷⁷Lu-lilotomab satetraxetan. Two of the arms, 1 and 4, are continued in phase 2 as indicated